Fig. 3
From: Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy
P1 imaging and functional assessments. P1 fundus picture OU at presentation (a). OCT line OD showed new cystic macular edema, which improved after rituximab infusions (b). Humphrey visual field (HVF) 10–2 OD grey scale and pattern standard deviation showed diffuse peripheral loss while on infliximab (2012, left), which stabilized after a few months on rituximab infusions (2015, right) (c). Western blot analysis after 7 months (top) and 14 months (bottom) on rituximab showed almost complete absence of reaction at follow-up (d)